BOSTON, April 30, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease (the "Company" or "Keryx"), today announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison.
"This is a very exciting time in the evolution of Keryx and I am honored to be taking the helm of our company at this juncture," said Greg Madison, the Chief Executive Officer of Keryx. "Over the course of 2014, Keryx completed the transition from a development-stage company to a fully integrated commercial organization, culminating with the FDA approval and commercial launch of Auryxia™ (ferric citrate) in the United States. The entire Keryx organization is thankful to Ron for all that he has done for our company and we wish him well in his future endeavors."
As per Mr. Bentsur's employment agreement, Mr. Bentsur will also be stepping down from the Company's Board of Directors, which will be reduced to seven members.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the Company launched its first FDA-approved product, Auryxia (ferric citrate) for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
Some of the statements included in this press release, particularly those regarding the commercialization and subsequent clinical development of Auryxia, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether Auryxia will be successfully launched and marketed in the U.S.; whether Riona® will be successfully marketed in Japan by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd; the risk that the EMA may not concur with our interpretation of our Phase 3 study results, supportive data, conduct of the studies, or any other part of our MAA submission and could ultimately deny approval of the MAA; the risk that we may not be successful in the development of Auryxia for the treatment of iron deficiency anemia in non-dialysis dependent chronic kidney disease patients; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT: KERYX CONTACT: Amy Sullivan Vice President, Corporate Development and Public Affairs Tel: 617.466.3447 E-mail: firstname.lastname@example.org
Source:Keryx Biopharmaceuticals, Inc.